FDA approves AstraZeneca/Pozen's Vimovo
This article was originally published in Scrip
Executive Summary
The US FDA has approved AstraZeneca and Pozen's Vimovo (naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.